Vulnerability Identified for Subtypes of Glioblastoma
Precision medicine approach may give previously tested drug a second chance
Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. University of California San Diego School of Medicine researchers identified a strategy that pinpoints a genetically distinct subpopulation of patients with glioblastoma that is particularly sensitive to drugs like cilengitide that target a cell adhesion receptor.
Cilengitide was developed based on early studies by David Cheresh, PhD, Distinguished Professor of Pathology at UC San Diego School of Medicine, and colleagues who demonstrated that expression was linked to the progression of glioblastoma. The drug was tested in clinical trials but production was halted in 2014 when it failed to show significant improvement in overall survival among participants during phase III trials.
Click here to read more.
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York
Minimally Invasive Cranial Neurosurgery: Recent Technical Advances With Hands-On Laboratory
June 7-8, 2019; New York
The 25th Annual Meeting of the Organization for Human Brain Mapping (OHBM 2019)
June 9-13, 2019; Rome